Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317749 | 0.82 | HRH3 (0.60) | HRH3HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6135913 | 0.80 | LMNA (0.56) | HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1014002 | 0.79 | HPGD (0.86) | HRH3HPGDSMN1; SMN2USP2TSHR | |
| SCHEMBL3318521 | 0.78 | FAAH (0.54) | HRH3HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4954284 | 0.78 | L3MBTL1 (0.47) | SMN1; SMN2USP2TSHRGAA | |
| SCHEMBL10184001 | 0.78 | HRH3 (0.78) | HRH3HPGDSMN1; SMN2USP2TSHR | |
| SCHEMBL3320543 | 0.77 | FAAH (0.52) | MEN1KMT2ASMN1; SMN2USP2TSHR | |
| SCHEMBL13636330 | 0.76 | HRH3 (1.00) | HRH3HPGDSMN1; SMN2USP2TSHR | |
| SCHEMBL3320389 | 0.76 | MEN1 (0.61) | HPGDMEN1KMT2ASMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL1177194 | 0.75 | HRH3 (0.97) | HRH3HPGDSMN1; SMN2USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-20050065095-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-03-24 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| EP-1202968-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010834-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065095-A1 | Antibacterial agents | NQO2, DAO, Q6ZSR9 | HRH3 139/4885HPGD 1305/4885MEN1 2824/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | HRH3 104/4885HPGD 1389/4885MEN1 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.